SOLICITATION NOTICE
A -- Development of Advanced Long-term Biomarkers of Exposure to Cholinesterase Inhibitors.
- Notice Date
- 4/4/2013
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2013-N-15032
- Archive Date
- 5/4/2013
- Point of Contact
- Liubov A. Kriel, Phone: 7704882856
- E-Mail Address
-
vyh1@cdc.gov
(vyh1@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC)/ National Center for Environmental Health (NCEH)/ Division of Laboratory Sciences (DLS)/ Emergency Response Branch (ERB) intends to award a sole source contract to University of Washington Medical School, Departments of Medicine (Div. Medical Genetics) and Genome Sciences, Organophosphorus Exposure Laboratory, PO Box 357720, Seattle, WA 98195-7720, for the acquisition of the effort entitled, "Development of Advanced Long-term Biomarkers of Exposure to Cholinesterase Inhibitors." The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 611310, Colleges, Universities, and Professional Schools. The purpose of this acquisition is to identify and develop new protein biomarkers for assessing exposure to cholinesterase inhibitors in clinical samples. The result of this project will be incorporated in the methodology used within the CDC/NCEH/DLS/ERB/CT Method Development Laboratory for the assessment of human exposure to organophosphorus nerve agents. The Organophosphorus Exposure Laboratory of the University of Washington is the only laboratory to meet all the requirements of the effort. It has access to a wide variety of human clinical samples including serum/plasma and whole blood inhibited by organophosphorus compounds including nerve agents, jet engine lubricant additives, and pesticides; such access is an absolute requirement for protein biomarker discovery. Also, this lab is a respected, international leader in the field of cholinesterases and has a proven track record for developing new biomarkers of exposure to cholinesterase inhibitors. The laboratory has unique experience in assessing cholinesterase inhibitor effects on enzymatic activity and is the only lab in the world known to have the capability to use analysis of blood spots for assessing exposure to OP compounds. In addition, the laboratory is the only one capable of testing any new potential biomarkers using the same immunomagnetic separation (IMS) liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach that is utilized in CDC's clinical assays for assessing exposure to OPNAs. This laboratory has access to state of the art high resolution tandem mass spectrometers and detailed experience using this equipment for discovery based and quantitative proteomics. The Organophosphorus Exposure Laboratory at the University of Washington Medical School is the primary contributor to biomarker discovery in this field and is the only resource that satisfies all of the requirements for this request. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to the University of Washington. However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contract Specialist by April 19, 2013. The Contract Specialist will not respond to verbal request. All requests must be in writing. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall be sent to Liubov Kriel by email at vyh1@cdc.gov and reference solicitation number 2013-N-15032 on the subject line.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2013-N-15032/listing.html)
- Place of Performance
- Address: Contractor's Facility, Seattle, Washington, United States
- Record
- SN03028887-W 20130406/130404234837-9316229a664ca46ae31987fe4e1f7a04 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |